Anti-Proteinase 3/PR3 Antibody, clone 1L13 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry. This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 1L13 is a ZooMAb^® rabbit recombinant monoclonal antibody that specifically detects Proteinase 3 (PR3). It targets an epitope within 15 amino acids from the internal region.

KLH-conjugated linear peptide corresponding to 15 amino acids from the internal region of human Proteinase 3 (PR3).

Quality Control Testing

Evaluated by Western Blotting in HL-60 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected Proteinase 3/PR3 in HL-60 cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected Proteinase 3/PR3 in Human bone marrow tissue lysate.

Affinity Binding Assay: A representative lot of this antibody bound Proteinase 3/PR3 peptide with a KD of 7.0 x 10-8 in an affinity binding assay.

Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected Proteinase 3/PR3 in Human bone marrow tissue sections.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected Proteinase 3/PR3 in HL-60 cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Myeloblastin (UniProt P24158; also known as EC 3.4.21.76, AGP7, C-ANCA antigen, Leukocyte proteinase 3, Neutrophil proteinase 4, NP-4, P29, PR-3, PR3, Wegener autoantigen) is encoded by the PRTN3 (also known as CANCA, MBN, NP4) gene (Gene ID: 5657) in human. Proteinase 3 (PR3) is a serine protease that is synthesized with a signal peptide (aa 1-25) and a propeptide (aa 26-27) that are cleaved off to produce the mature protein. It is reported to modulate the activity of platelets, endothelial cells, and inflammatory mediators, such as IL-1, IL-8, and TNF . It is a weak cationic protease that degrades elastin, fibronectin, laminin, vitronectin, and collagens I, III, and IV. Its expression is observed only in human and non-human primates and is found in azurophile granules of polymorphonuclear leukocytes and monocytes. Following its synthesis, some of it translocates to the surface of neutrophil plasma membrane in either pro- or mature form. The degree of such surface expression is genetically determined, but its surface exposure and pericellular activity can be further upregulated upon neutrophil priming and activation. Proteinase 3 autoantibody (anti-neutrophil cytoplasmic antibodies or ANCA) is the main pathogenic feature in patients suffering from granulomatosis with polyangiitis (GPA). ANCAs are shown to activate cytokine-primed neutrophils in vitro by cross-linking surface-exposed proteinase 3 and Fc receptors. Proteinase 3 activity and/or its inactivation by 1-antitrypsin varies in the human population and contributes to the risk for GPA manifestations either at onset, during relapses, or during systemic progression. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Granel, J., et al. (2021). Front. Immunol. 12; :571933; Rao, NV., et al (1991). J. Biol. Chem. 266(15); 9540-9548).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.